Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Tian TV"'
Autor:
Torcal Garcia, Guillem, Kowenz-Leutz, Elisabeth, TIAN, TIAN, Klonizakis, Antonis, Lerner, Jonathan, de Andres-Aguayo, Luisa, Vila-Casadesús, Maria, Peiró, Sandra
Publikováno v:
Scientia
Developmental biology; Gene regulation; Transcription factor Biologia del desenvolupament; Regulació gènica; Factor de transcripció Biología del desarrollo; Regulación génica; Factor de transcripción Here, we describe how the speed of C/EBPα-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3991::983557d30f74aa778dfab87fcce6a4da
https://hdl.handle.net/11351/9933
https://hdl.handle.net/11351/9933
Autor:
Queralt Serra-Camprubí, Helena Verdaguer, Winona Oliveros, Núria Lupión-Garcia, Alba Llop-Guevara, Cristina Molina, Maria Vila-Casadesús, Anthony Turpin, Cindy Neuzillet, Joan Frigola, Jessica Querol, Mariana Yáñez-Bartolomé, Florian Castet, Carles Fabregat-Franco, Carmen Escudero-Iriarte, Marta Escorihuela, Enrique J. Arenas, Cristina Bernadó-Morales, Noemí Haro, Francis J. Giles, Óscar J. Pozo, Josep M. Miquel, Paolo G. Nuciforo, Ana Vivancos, Marta Melé, Violeta Serra, Joaquín Arribas, Josep Tabernero, Sandra Peiró, Teresa Macarulla, Tian V. Tian
Publikováno v:
Scientia
Cholangiocarcinoma (CCA) is usually diagnosed at advanced stages, with limited therapeutic options. Preclinical models focused on unresectable metastatic CCA are necessary to develop rational treatments. Pathogenic mutations in IDH1/2, ARID1A/B, BAP1
Autor:
Marcos Plana-Carmona, Gregoire Stik, Romain Bulteau, Carolina Segura-Morales, Noelia Alcázar, Chris D.R. Wyatt, Antonios Klonizakis, Luisa de Andrés-Aguayo, Maxime Gasnier, Tian V. Tian, Guillem Torcal Garcia, Maria Vila-Casadesús, Nicolas Plachta, Manuel Serrano, Mirko Francesconi, Thomas Graf
Publikováno v:
Scientia
Dipòsit Digital de la UB
Universidad de Barcelona
Dipòsit Digital de la UB
Universidad de Barcelona
Gene regulation; Somatic cell reprogramming; Trophectoderm Regulación de genes; Reprogramación de células somáticas; Trofoectodermo Regulació de gens; Reprogramació de cèl·lules somàtiques; Trofectoderma IL-6 has been shown to be required fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6feea39aed563f58758ad5e0eaa604c4
http://hdl.handle.net/2445/189064
http://hdl.handle.net/2445/189064
Publikováno v:
Scientia
Cèl·lules mare embrionàries; Seqüenciació d'alt rendiment Células madre embrionarias; Secuenciación de alto rendimiento Embryonic stem cells; High-throughput sequencing During mammalian development, cell fates are determined through the establ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d31a754a8bbf5a29c9fbe3d81f83722
http://hdl.handle.net/10230/45510
http://hdl.handle.net/10230/45510
Autor:
González-Medina A; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Vila-Casadesús M; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Gomez-Rey M; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Fabregat-Franco C; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Upper Gastrointestinal and Endocrine Tumor Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Sierra A; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Tian TV; Upper Gastrointestinal and Endocrine Tumor Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Castet F; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Upper Gastrointestinal and Endocrine Tumor Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Castillo G; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Matito J; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Martinez P; Molecular Oncology Lab, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Miquel JM; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Nuciforo P; Molecular Oncology Lab, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Pérez-López R; Radiomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Macarulla T; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Upper Gastrointestinal and Endocrine Tumor Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Vivancos A; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Oct 01; Vol. 30 (19), pp. 4491-4504.
Autor:
Serra-Bardenys G; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Institut Bonanova FP Sanitaria, Consorci Mar Parc de Salut de Barcelona, Spain., Blanco E; Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Spain., Escudero-Iriarte C; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Serra-Camprubí Q; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Querol J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Pascual-Reguant L; Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Spain., Morancho B; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Escorihuela M; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Tissera NS; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Sabé A; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Martín L; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Segura-Bayona S; The Francis Crick Institute, London, UK., Verde G; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Aiese Cigliano R; Sequentia Biotech SL, Barcelona, Spain., Millanes-Romero A; Institute for Research in Biomedicine (IRB Barcelona) and Barcelona Institute of Science and Technology, Spain., Jerónimo C; Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Spain.; Institut de Recherches Cliniques de Montréal, Canada., Cebrià-Costa JP; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Nuciforo P; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Simonetti S; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Viaplana C; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Dienstmann R; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Oliveira M; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Peg V; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Barcelona, Spain.; Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.; Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain., Stracker TH; Radiation Oncology Branch, National Cancer Institute, Bethesda, MD, USA., Arribas J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.; Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain., Canals F; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Villanueva J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Di Croce L; Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain., García de Herreros A; Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain.; Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain., Tian TV; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Peiró S; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Publikováno v:
The FEBS journal [FEBS J] 2024 Jun; Vol. 291 (11), pp. 2423-2448. Date of Electronic Publication: 2024 Mar 07.
Autor:
Luk IS; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Bridgwater CM; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Yu A; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Boila LD; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Yáñez-Bartolomé M; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Lampano AE; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Hulahan TS; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Boukhali M; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA., Kathiresan M; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA., Macarulla T; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Gastrointestinal and Endocrine Tumor Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain., Kenerson HL; Department of Surgery, University of Washington, Seattle, WA 98195, USA., Yamamoto N; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Medical Scientist Training Program, University of Washington, Seattle, WA 98195, USA., Sokolov D; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Engstrom IA; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Sullivan LB; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Lampe PD; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Cooper JA; Basic Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Yeung RS; Department of Surgery, University of Washington, Seattle, WA 98195, USA., Tian TV; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Haas W; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA., Saha SK; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Kugel S; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Publikováno v:
Science translational medicine [Sci Transl Med] 2024 May 15; Vol. 16 (747), pp. eadj7685. Date of Electronic Publication: 2024 May 15.
Autor:
Yáñez-Bartolomé M; Upper GI and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Serra-Camprubí Q; Upper GI and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Arenas EJ; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Escorihuela M; Growth Factor Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Castet F; Upper GI and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Fabregat-Franco C; Upper GI and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Querol J; Upper GI and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Arribas J; Growth Factor Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, Madrid, Spain.; Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain.; Cancer Research Program, Hospital de Mar Medical Research Institute (IMIM), Barcelona, Spain.; Institució Catalana de Recerca I Estudis Avançats (ICREA), Barcelona, Spain., Peiró S; Upper GI and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Macarulla T; Upper GI and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. tmacarulla@vhio.net., Tian TV; Upper GI and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. tiantian@vhio.net.
Publikováno v:
Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2024; Vol. 2806, pp. 139-151.
Autor:
Pascual-Reguant L; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain., Serra-Camprubí Q; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Datta D; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain., Cianferoni D; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain., Kourtis S; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain., Gañez-Zapater A; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain., Cannatá C; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain., Espinar L; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain., Querol J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., García-López L; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain., Musa-Afaneh S; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain., Guirola M; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain., Gkanogiannis A; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain., Miró Canturri A; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain., Guzman M; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Rodríguez O; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Herencia-Ropero A; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Arribas J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, Madrid, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autónoma de Barcelona, Bellaterra, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain., Serra V; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Serrano L; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain., Tian TV; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Peiró S; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Sdelci S; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Publikováno v:
EMBO molecular medicine [EMBO Mol Med] 2023 Dec 07; Vol. 15 (12), pp. e18459. Date of Electronic Publication: 2023 Nov 08.
Autor:
Turpin A; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Department of Medical Oncology, Lille University Hospital, F-59000, Lille, France., Delliaux C; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Parent P; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Department of Medical Oncology, Lille University Hospital, F-59000, Lille, France., Chevalier H; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Department of Medical Oncology, Centre Oscar Lambret, 3, rue Frederic Combemale, 59000, Lille, France., Escudero-Iriarte C; Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain., Bonardi F; University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, F-59000, Lille, France., Vanpouille N; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Flourens A; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Querol J; Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain., Carnot A; Department of Medical Oncology, Centre Oscar Lambret, 3, rue Frederic Combemale, 59000, Lille, France., Leroy X; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Institut de Pathologie, CHU Lille, Avenue Oscar Lambret, F-59000, Lille, France., Herranz N; Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain., Lanel T; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Institut de Pathologie, CHU Lille, Avenue Oscar Lambret, F-59000, Lille, France., Villers A; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Department of Urology, Hospital Claude Huriez, CHU Lille, Lille, France., Olivier J; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Department of Urology, Hospital Claude Huriez, CHU Lille, Lille, France., Touzet H; University Lille, CNRS, Centrale Lille, UMR 9189 CRIStAL, F-59000, Lille, France., de Launoit Y; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Tian TV; Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain., Duterque-Coquillaud M; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France. martine.duterque@cnrs.fr.
Publikováno v:
British journal of cancer [Br J Cancer] 2023 Dec; Vol. 129 (12), pp. 1903-1914. Date of Electronic Publication: 2023 Oct 24.